334 related articles for article (PubMed ID: 21472373)
1. Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial.
Verelst SG; Termorshuizen F; Uyl-de Groot CA; Schaafsma MR; Ammerlaan AH; Wittebol S; Sinnige HA; Zweegman S; van Marwijk Kooy M; van der Griend R; Lokhorst HM; Sonneveld P; Wijermans PW;
Ann Hematol; 2011 Dec; 90(12):1427-39. PubMed ID: 21472373
[TBL] [Abstract][Full Text] [Related]
2. Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial.
Delforge M; Dhawan R; Robinson D; Meunier J; Regnault A; Esseltine DL; Cakana A; van de Velde H; Richardson PG; San Miguel JF
Eur J Haematol; 2012 Jul; 89(1):16-27. PubMed ID: 22469559
[TBL] [Abstract][Full Text] [Related]
3. Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group.
Beksac M; Haznedar R; Firatli-Tuglular T; Ozdogu H; Aydogdu I; Konuk N; Sucak G; Kaygusuz I; Karakus S; Kaya E; Ali R; Gulbas Z; Ozet G; Goker H; Undar L
Eur J Haematol; 2011 Jan; 86(1):16-22. PubMed ID: 20942865
[TBL] [Abstract][Full Text] [Related]
4. Interpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical importance of score differences.
Gulbrandsen N; Hjermstad MJ; Wisløff F;
Eur J Haematol; 2004 Mar; 72(3):172-80. PubMed ID: 14962235
[TBL] [Abstract][Full Text] [Related]
5. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.
Palumbo A; Bringhen S; Caravita T; Merla E; Capparella V; Callea V; Cangialosi C; Grasso M; Rossini F; Galli M; Catalano L; Zamagni E; Petrucci MT; De Stefano V; Ceccarelli M; Ambrosini MT; Avonto I; Falco P; Ciccone G; Liberati AM; Musto P; Boccadoro M;
Lancet; 2006 Mar; 367(9513):825-31. PubMed ID: 16530576
[TBL] [Abstract][Full Text] [Related]
6. Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis.
Kapoor P; Rajkumar SV; Dispenzieri A; Gertz MA; Lacy MQ; Dingli D; Mikhael JR; Roy V; Kyle RA; Greipp PR; Kumar S; Mandrekar SJ
Leukemia; 2011 Apr; 25(4):689-96. PubMed ID: 21233832
[TBL] [Abstract][Full Text] [Related]
7. Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study.
Wijermans P; Schaafsma M; Termorshuizen F; Ammerlaan R; Wittebol S; Sinnige H; Zweegman S; van Marwijk Kooy M; van der Griend R; Lokhorst H; Sonneveld P;
J Clin Oncol; 2010 Jul; 28(19):3160-6. PubMed ID: 20516439
[TBL] [Abstract][Full Text] [Related]
8. Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma.
Palumbo A; Bertola A; Musto P; Caravita T; Callea V; Nunzi M; Grasso M; Falco P; Cangialosi C; Boccadoro M
Cancer; 2005 Oct; 104(7):1428-33. PubMed ID: 16116606
[TBL] [Abstract][Full Text] [Related]
9. Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma.
Palumbo A; Davies F; Kropff M; Bladé J; Delforge M; Leal da Costa F; Garcia Sanz R; Schey S; Facon T; Morgan G; Moreau P
Ann Hematol; 2010 Aug; 89(8):803-11. PubMed ID: 20232066
[TBL] [Abstract][Full Text] [Related]
10. Frontline treatment of multiple myeloma in elderly patients.
Moreau P; Hulin C; Facon T
Blood Rev; 2008 Nov; 22(6):303-9. PubMed ID: 18550234
[TBL] [Abstract][Full Text] [Related]
11. Addition of thalidomide to melphalan and prednisone treatment prolongs survival in multiple myeloma--a retrospective population based study of 1162 patients.
Lund J; Uttervall K; Liwing J; Gahrton G; Alici E; Aschan J; Holmberg E; Nahi H
Eur J Haematol; 2014 Jan; 92(1):19-25. PubMed ID: 24118547
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
Hulin C; Facon T; Rodon P; Pegourie B; Benboubker L; Doyen C; Dib M; Guillerm G; Salles B; Eschard JP; Lenain P; Casassus P; Azaïs I; Decaux O; Garderet L; Mathiot C; Fontan J; Lafon I; Virion JM; Moreau P
J Clin Oncol; 2009 Aug; 27(22):3664-70. PubMed ID: 19451428
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study.
Morabito F; Bringhen S; Larocca A; Wijermans P; Victoria Mateos M; Gimsing P; Mazzone C; Gottardi D; Omedè P; Zweegman S; José Lahuerta J; Zambello R; Musto P; Magarotto V; Schaafsma M; Oriol A; Juliusson G; Cerrato C; Catalano L; Gentile M; Isabel Turel A; Marina Liberati A; Cavalli M; Rossi D; Passera R; Rosso S; Beksac M; Cavo M; Waage A; San Miguel J; Boccadoro M; Sonneveld P; Palumbo A; Offidani M
Am J Hematol; 2014 Apr; 89(4):355-62. PubMed ID: 24273190
[TBL] [Abstract][Full Text] [Related]
14. A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant.
Sacchi S; Marcheselli R; Lazzaro A; Morabito F; Fragasso A; Di Renzo N; Balleari E; Neri S; Quarta G; Ferrara R; Vigliotti ML; Polimeno G; Musto P; Consoli U; Zoboli A; Buda G; Pastorini A; Masini L
Leuk Lymphoma; 2011 Oct; 52(10):1942-8. PubMed ID: 21663513
[TBL] [Abstract][Full Text] [Related]
15. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.
Facon T; Mary JY; Hulin C; Benboubker L; Attal M; Pegourie B; Renaud M; Harousseau JL; Guillerm G; Chaleteix C; Dib M; Voillat L; Maisonneuve H; Troncy J; Dorvaux V; Monconduit M; Martin C; Casassus P; Jaubert J; Jardel H; Doyen C; Kolb B; Anglaret B; Grosbois B; Yakoub-Agha I; Mathiot C; Avet-Loiseau H;
Lancet; 2007 Oct; 370(9594):1209-18. PubMed ID: 17920916
[TBL] [Abstract][Full Text] [Related]
16. Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study.
Nielsen LK; Stege C; Lissenberg-Witte B; van der Holt B; Mellqvist UH; Salomo M; Bos G; Levin MD; Visser-Wisselaar H; Hansson M; van der Velden A; Deenik W; Coenen J; Hinge M; Klein S; Tanis B; Szatkowski D; Brouwer R; Westerman M; Leys R; Sinnige H; Haukås E; van der Hem K; Durian M; Gimsing P; van de Donk N; Sonneveld P; Waage A; Abildgaard N; Zweegman S
Haematologica; 2020 Jun; 105(6):1650-1659. PubMed ID: 31515355
[TBL] [Abstract][Full Text] [Related]
17. Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma.
Zweegman S; van der Holt B; Mellqvist UH; Salomo M; Bos GM; Levin MD; Visser-Wisselaar H; Hansson M; van der Velden AW; Deenik W; Gruber A; Coenen JL; Plesner T; Klein SK; Tanis BC; Szatkowski DL; Brouwer RE; Westerman M; Leys MR; Sinnige HA; Haukås E; van der Hem KG; Durian MF; Mattijssen EV; van de Donk NW; Stevens-Kroef MJ; Sonneveld P; Waage A
Blood; 2016 Mar; 127(9):1109-16. PubMed ID: 26802176
[TBL] [Abstract][Full Text] [Related]
18. The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation.
Picot J; Cooper K; Bryant J; Clegg AJ
Health Technol Assess; 2011 Dec; 15(41):1-204. PubMed ID: 22146234
[TBL] [Abstract][Full Text] [Related]
19. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma.
Cocks K; Cohen D; Wisløff F; Sezer O; Lee S; Hippe E; Gimsing P; Turesson I; Hajek R; Smith A; Graham L; Phillips A; Stead M; Velikova G; Brown J;
Eur J Cancer; 2007 Jul; 43(11):1670-8. PubMed ID: 17574838
[TBL] [Abstract][Full Text] [Related]
20. Thalidomide-based Regimens for Elderly and/or Transplant Ineligible Patients with Multiple Myeloma: A Meta-analysis.
Lyu WW; Zhao QC; Song DH; Zhang JJ; Ding ZX; Li BY; Wei CM
Chin Med J (Engl); 2016 Feb; 129(3):320-5. PubMed ID: 26831235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
